Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions

View Full Paper
Ask AI
Bookmark
Share

Authors

CMClemens MellinkHSHanneke van der StraatenWPWard Posthuma

Discussion

Loading...

Member takes

Overview

Observational analysis reports improved disease control in untreated CLL patients after obinutuzumab-venetoclax treatment, suggesting effective management strategies.

Key Points

  • Median progression-free survival (PFS) was 86.4 months, indicating lasting efficacy of obinutuzumab-venetoclax.
  • In a cohort of 67 patients, 31% required second line treatment at a median of 70 months post-initial therapy.
  • Assessment included untreated CLL patients with high-risk characteristics like TP53 aberrations; results support these approaches.
  • Findings highlight possible benefits and enduring disease control, relevant for treatment planning in less-fit CLL patients.

Cite This Study

Mellink et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e21bhttps://doi.org/10.1182/blood-2025-3897
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia2025 · 1 citations
  2. 2Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  3. 3Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial2025
  4. 4Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 4 citations
  5. 5Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations